Aim: To assess the burden of congenital and perinatal cytomegalovirus (CMV) disease among infants hospitalized in neonatal intensive care units (NICUs). Methods: CMV infection was defined as a report of positive CMV viral culture or polymerase chain reaction at any time since birth in an infant hospitalized in a NICU reporting to California Perinatal Quality Care Collaborative during [2005][2006][2007][2008][2009][2010]. Results: One hundred and fifty-six (1.7 per 1000) infants were reported with CMV infection, representing an estimated 5% of the expected number of live births with symptomatic CMV disease. Prevalence was higher among infants with younger gestational ages and lower birth weights. Infants with CMV infection had significantly longer hospital stays and 14 (9%) died.
Introduction
In the USA, an estimated 28,000 (0.7%) infants are born with congenital cytomegalovirus (CMV) infection annually, 3600 (12.7%) of whom are estimated to be symptomatic at birth [6] . Symptomatic congenital CMV disease is characterized by petechiae, purpura, thrombocytopenia, hepatosplenomegaly, direct hyperbilirubinemia, microcephaly, intracranial calcifications, chorioretinitis, and hearing impairment [4, 10] . To confirm a diagnosis of congenital CMV infection, CMV must be detected in urine, saliva, or blood within 2-3 weeks of birth [19, 27] . In a study of dried blood samples collected for newborn screening, the prevalence of congenital CMV infection was significantly higher among preterm and low birth weight infants [13] . As such, the prevalence of congenital CMV infection among infants admitted to neonatal intensive care units (NICUs) is likely higher than that of the overall population [22, 26, 28] .
A subset of the NICU population, infants born < 32 weeks of gestational age or with a birth weight < 1500 g, is at risk for symptomatic CMV disease [7] from infection acquired peri-or postnatally through exposure to infected maternal genital secretions, breast milk, or blood transfusion [32] . The risk of CMV transmission by blood transfusion can be reduced by the use of CMV-seronegative or leukocyte-reduced blood components [2, 18, 35] , which have become the standard of care for premature infants in the United States [2, 11, 31] ; most CMV infections in neonates are likely transmitted by breast milk [7, 17, 34] . The clinical characteristics associated with postnatallyacquired CMV infection include hepatopathy, thrombocytopenia, neutropenia, petechiae, respiratory distress syndrome, and sepsis-like syndrome [7, 34] .
Limited data are available on the burden of CMV disease in infancy and the extent to which it is severe enough to require hospitalization in NICUs. This study describes demographic and clinical characteristics of infants with reported CMV infection in California NICUs during 2005-2010 and estimates the proportion of expected live births with symptomatic congenital or acquired CMV disease identified in California NICUs during the study period.
Methods

Study population
The California Perinatal Quality Care Collaborative (CPQCC) collects data for over 90% of infants cared for in California NICUs [8, 20] . Eligibility criteria include admission to a NICU at birth or within 28 days of life and one of the following: (i) birth weight between 401 g and 1500 g; (ii) gestational age between 22 weeks and 29+6 weeks; or (iii) for infants with birth weight > 1500 g, either death, surgery, intubation for > 4 h, positive pressure support for > 4 h, hyperbilirubinemia, early bacterial sepsis, or acute transfer.
A comprehensive questionnaire including demographics, maternal and delivery history, post-delivery diagnoses, and interventions is used to collect data for each eligible infant. Data are abstracted by NICU personnel (i.e., physicians, nurses, and other trained abstractors) and submitted electronically or online. As the current definition of congenital CMV infection used by CPQCC is based on documentation of a positive viral culture or PCR for CMV at any time since birth, it is possible that infants with hospitalizations lasting beyond the first 3 weeks after birth had peri-or postnatally acquired CMV infection; 136 (87%) infants reported with CMV infection were discharged or died after 3 weeks of life. Specimen type and date of collection were not recorded, precluding our ability to verify the diagnosis and categorize infants as having congenital or acquired CMV infection.
Data analysis
This study utilized data from 2005-2010 to assess the prevalence of CMV infection per 1000 live births, using as a denominator the number of live births reported to the CPQCC. The following clinical characteristics were available for analysis: antenatal conditions [fetal distress, intrauterine growth retardation (IUGR), any anomaly diagnosed prior to birth], Apgar at 1 st min, respiratory distress syndrome, neurologic abnormalities [microcephaly, seizure, cystic periventricular leukomalacia, and periventricular-intraventricular hemorrhage (PIH)], death, and length of hospital stay.
Microcephaly was defined as reported head circumference measured on the day of birth or the following day ≤ 10 th percentile according to US growth charts of preterm infants [25] . Cystic periventricular leukomalacia and PIH were identified by cranial ultrasound, computerized tomographic scan or magnetic resonance imaging performed on or before 28 days of life. PIH was graded as follows: 0 for no subependymal or intraventricular hemorrhage; 1 for subependymal germinal matrix hemorrhage only; 2 for intraventricular blood, without ventricular dilation; 3 for intraventricular blood with ventricular dilation; and 4 for intraparenchymal hemorrhage.
In univariate analyses, clinical characteristics of infants with and without reported CMV infection were compared. Analyses of clinical characteristics were performed for very low birth weight (VLBW) infants (those with birth weight between 401-1500 g) and infants weighing > 1500 g. Infants with other congenital or perinatal infections, such as herpes simplex virus and HIV, were excluded from the analyses. Statistical analyses, performed using SAS version 9.3 (SAS, Cary, NC, USA), were based on χ 2 -test or exact test for comparison of categorical variables, Chi-square for linear trend, and the Wilcoxon test for continuous variables.
The proportion of the expected number of live births with symptomatic CMV disease in California that were identified in California NICUs was estimated assuming all infants reported with CMV infection would have symptomatic disease, given that CMV-specific testing among infants in the United States appears to be conducted primarily for diagnostic purposes [21] . CPQCC average coverage of California NICUs of 87% (85% during 2005-2008 and 90% during 2009-2010) was used to extrapolate the number of live births reported with CMV infection in CPQCC-member hospitals to the entire state of California. The expected number of live births with symptomatic congenital CMV disease was derived assuming an annual birth prevalence of congenital CMV infection of 0.7%, with 12.7% of infected live births presenting with symptomatic congenital CMV disease [6] . The expected number of live births with symptomatic acquired CMV disease was estimated assuming that symptomatic disease from peri-or postnatally acquired infection was limited to live births < 32 weeks gestational age or with a birth weight < 1500 g, with an incidence rate of 2.4% [17] .
The study protocol was submitted to the Institutional Review Boards at the Centers for Disease Control and Prevention and Stanford University and deemed exempt from further review because all data were de-identified.
Results
During 2005-2010, 156 of 91,435 infants in CPQCC-member hospital NICUs were reported as having CMV infection; 87 of 33,588 VLBW infants and 69 of 57,847 infants > 1500 g. This corresponds to an overall prevalence of 1.7 infants reported with CMV infection per 1000 live births requiring NICU care; 2.6 per 1000 among VLBW infants and 1.2 per 1000 among infants > 1500 g. The prevalence of CMV infection increased from 1.1 to 2.5 per 1000 live births during 2005-2010 with marked increases among VLBW infants (1.5 to 4.6 per 1000 live births) ( Figure 1 ). The prevalence of CMV infection was higher among infants with younger gestational age ( < 32 weeks: 2.4 per 1000, 32-36 weeks: 1.4 per 1000, and ≥ 37 weeks: 1.2 per 1000), and among infants with lower birth weight ( < 1500 g: 2.6 per 1000, 1501-2500 g: 1.8 per 1000, and > 2500 g: 0.8 per 1000) (P < 0.01).
The majority of infants reported with CMV infection were born to mothers 20-29 years of age (44%) ( Table 1 ). The prevalence of CMV infection was highest among infants born to mothers < 20 years of age, 1.8-fold that of infants born to mothers 30-39 years of age. The highest prevalence of CMV infection was observed among infants born to Asian/Pacific Islander mothers (3.4 per 1000 live births), followed by those born to Hispanics (1.8 per 1000 live births) and non-Hispanic blacks (1.7 per 1000 live births). Among VLBW infants, the prevalence of CMV infection among infants born to Asian/ Pacific Islander mothers was nearly 3-fold that of infants of infants born to non-Hispanic white mothers (PR = 1.9; 95% CI = 1.1-3.5).
Overall, IUGR was diagnosed in 25 (17%) infants reported with CMV infection, and was more common than in infants without CMV infection (Table 2) . Among infants > 1500 g, 15 (23%) with CMV infection had anomalies detected prior to birth (brain anomalies, cardiac defects, or gastrointestinal malformations) two times as many as those without CMV infection (P < 0.05). The proportion of infants with Apgar scores ≤ 3 did not differ by CMV status, even after stratification by birth weight. VLBW infants with CMV infection were more likely than those without CMV infection to have respiratory distress syndrome [odds ratio (OR) = 2.5; 95% CI = 1.3-4.7] (P < 0.01). Although only two infants reported with CMV infection had microcephaly listed as a congenital anomaly, 19 (14%) infants with CMV infection were determined to have head circumference ≤ 3 rd percentile, and 42 (31%) had microcephaly (head circumference ≤ 10 th percentile). Microcephaly was more common among infants with CMV infection (P < 0.05).
Among infants reported with CMV infection, 99% of VLBW infants and 81% of infants > 1500 g were hospitalized in a NICU beginning in the 1 st day of life. Fourteen (9%) infants reported with CMV infection died, including eight (9%) of the VLBW infants and six (9%) of the infants > 1500 g (Table 2 ), at a median of 38 (range: 3-99) born to non-Hispanic white mothers [prevalence ratio (PR) = 2.9; 95% confidence interval (CI) = 1.5-5.5]. Among infants > 1500 g, the prevalence of CMV infection among infants born to Hispanic mothers was nearly 2-fold that (25) 21 (24) 7023 (22) 16 (25) 9388 ( (27) 28 (33) 8827 (27) 13 (20) 7410 ( (14) 11 (14) 2206 (9) 8 (14) 1478 (3) (28) 27 (31) 7764 (27) 15 (25) 2214 (9) and nine (range: 3-107) days of life, respectively. Among infants > 1500 g, the frequency of death was significantly higher among those with CMV infection. Among surviving infants with CMV infection, the median length of hospital stay was 99 (interquartile range: 72-125) days for VLBW infants and 48 (18-76) days for infants > 1500 g, which was significantly longer than for those without CMV infection, 60 (42-86) days for VLBW infants and 14 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ) days for infants > 1500 g (P < 0.01).
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Discussion
Limited data are available on the burden of disease caused by congenital or acquired CMV infection among infants in the NICU setting [22, 26, 28] . While congenital CMV infection can result in severe disease [4, 10, 15] , the proportion of infants with disease severe enough to require NICU care is unknown. The overall reported prevalence of CMV infection was 1.7 per 1000 live births requiring NICU care in California, higher than the estimated prevalence of symptomatic congenital CMV disease in the general population (0.9 per 1000 live births) [6] . However, the proportion of infants identified with CMV infection in NICUs represents only a fraction of the total expected burden from symptomatic CMV disease, likely resulting from milder symptomatic cases that do not require NICU care. Nonetheless, CMV infection was associated with prolonged NICU stays, higher mortality rates, and neurological abnormalities.
Data on the prevalence of congenital or acquired CMV infection among NICU infants based on screening studies are limited. A study in Canada [33] found a prevalence of congenital CMV infection among VLBW infants of 1.5%. Another study in Spain [1] diagnosed 2.3% of VLBW infants with congenital CMV infection and 10.2% with peri-or postnatally acquired CMV infection. In our study, the true prevalence of CMV disease in NICUs was likely underestimated because even clinically apparent CMV infections may not be suspected or tested for in a timely manner, laboratory techniques have variable performance depending on the specimen type, and not all infections diagnosed may have been reported. Typical practice for considering and diagnosing CMV infection among NICU infants is currently unknown. The increasing prevalence of CMV infection in recent years of CPQCC data could reflect changing practices in CMV testing, diagnosis, and/ or reporting, and merits further investigation. Some of the infants reported in our study may have had asymptomatic CMV infection. Our major limitation was the inability to classify reported infants as having congenital or acquired CMV infection. As acquired CMV infection might occur in approximately 10% of VLBW infants [1, 17] , screening VLBW infants for CMV infection at birth would allow for distinguishing between congenital and acquired CMV infection, which have different prognoses for long-term sequelae and might simplify follow-up of these infants.
In our study, the prevalence of CMV infection increased with younger gestational age and lower birth weight. In Table 3 Proportion of expected number of live births with symptomatic congenital or acquired CMV disease identified in California NICUs 5%
a Estimates of birth prevalence of congenital CMV infection and proportion of symptomatic infants at birth according to a published systematic review of the literature [6] . Estimates of postnatal CMV disease acquired via consumption of frozen breast milk [17] . addition, CMV infection was associated with IUGR both in VLBW infants and infants > 1500 g. The mechanisms by the way CMV infection may be associated with prematurity and IUGR are not completely understood. Altered placental cytokine expression is associated with IUGR, prematurity, and early membrane rupture in uninfected pregnancies [3] . Recent studies suggest that CMV infection could result in proinflammatory changes with important consequences for placental development and function, virus transmission, and fetal viability [9, 30] . Understanding immune mechanisms at the level of the placenta associated with CMV transmission is an active area of research with the potential to aid the development of vaccines and immunotherapies [29] .
Microcephaly is a condition frequently reported among infants with congenital CMV disease [4, 10] , but it was reported as a congenital anomaly for only two infants with CMV infection in our study. When the criteria of head circumference ≤ 10 th percentile using appropriate population-based growth charts was applied, microcephaly was observed in 31% of infants with CMV infection. Microcephaly was more common among infants with reported CMV infection compared to those without CMV infection, both among VLBW infants and infants > 1500 g. While nearly all VLBW infants were routinely screened for brain abnormalities, among infants > 1500 g, it was more likely among those reported with CMV infection than those without, suggesting that this group more likely has true congenital CMV infection for which evaluation for brain abnormalities might be a routine practice. The role of neuroimaging is likely to evolve as more experience is gained with use of antiviral treatments for infants with congenital CMV-related neurologic abnormalities.
In populations with high maternal CMV seroprevalence, the birth prevalence of congenital CMV infection tends to be higher as does the acquisition of CMV through breastfeeding [5, 12] . A study using dried blood spots from a representative sample of newborns in California found the highest maternal IgG CMV seroprevalence in Hispanics (89%), followed by Asians (87%), blacks (77%), and whites (57%) [13] . In our study, the prevalence of CMV infection was highest among infants born to Asian/ Pacific Islander mothers (3.4 per 1000), followed by Hispanics (1.8 per 1000), non-Hispanic blacks (1.7 per 1000), and non-Hispanic whites (1.2 per 1000). Information on country of origin and other maternal sociodemographic variables that could have helped to better understand the higher prevalence of CMV infection observed among infants born to Asian/Pacific Islander mothers were not available.
Population-based studies are needed to better understand the spectrum of symptomatic congenital and acquired CMV disease, as well as the sub-groups of infants in whom disease is most prevalent. Understanding the proportion of cases of congenital and acquired CMV infection that are severe and require NICU care is important for assessing the burden and costs of CMV disease in infancy. In the absence of universal newborn screening, most cases of congenital CMV infection, both asymptomatic and symptomatic, are likely to be missed. Newborn screening for CMV has the potential to identify infants at risk of hearing loss and cognitive delays, although more data are needed on the interventions these infants would need and the benefit that prompt identification through early intervention could provide. More complete ascertainment of infants with symptomatic congenital CMV disease may facilitate appropriate selection of infants with central nervous system disease who would benefit from treatment with antivirals [14, 16, 23, 24] . In addition, data on burden of acquired CMV disease in VLBW and premature infants are important for guiding use of breast milk in this population [17] .
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